Anavex Life Sciences Corp (AVXL)

[Hoskuld]

We know exactly what the plan is - just as we do for all pre-revenue life sciences companies that are working to commercialize therapies for unmet needs: get approved to sell life-changing products that will generate revenue and profit. The great thing about biopharm is that you actually do know exactly what is going and and have an order of magnitude idea of timing and cost (yes, double both, at least.)

What you describe as a problem is not a problem. This is a waiting game and when the stock price goes down then there is loads of negative feelings that surface. If the stock was $30 per share then no one would be complaining. Right now we are seeing emotional reflexes kick in as the market delivers blows to our investment kneecaps, but the underlying business is just chugging along. We just have to wait for market sentiment and 2-73 data to drive AVXL the other way.